EUVIMEDEUVIMED entdecken
Übersichtsarbeit

A Review of Clonal Relationships in Myeloproliferative Neoplasms With Co-Mutations of JAK2, CALR or MPL and BCR::ABL1

Mohammadamin Noorafrooz, Sanaz Ghods, Robert Peter Gale, Ramin Noorafrooz

Clinical Lymphoma Myeloma and Leukemia · 2025

DOI: 10.1016/j.clml.2024.11.007 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025. Verfasst von Mohammadamin Noorafrooz und 3 weiteren Autor:innen. Beteiligte Einrichtung: Vali-E-Asr Reproductive Health Research Center, Family Health Research Institute, Tehran University of Medical Sciences, Tehran, Iran. Electronic add…. Hauptthemen laut MEDLINE: Janus Kinase 2, Myeloproliferative Disorders, Receptors, Thrombopoietin, Calreticulin. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 90 Literaturangaben. Gefördert von: National Institute for Health and Care Research, NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BCR::ABL1-negative myelo-proliferative neoplasms (MPNs) are characterized by mutations in JAK2, CALR, or MPL. Usually these mutations are co-exclusive of each other and of BCR::ABL1. We reviewed clonal interactions in 177 subjects with mutations in JAK2, CALR, or MPL and BCR::ABL1 including JAK2/BCR::ABL1 (N = 142), CALR/BCR::ABL1 (N = 31), MPL/BCR::ABL1 (N = 3). Co-mutations can arise in the same clone or in different sub-clones. In this review we used clonality data, mutation sequencing and therapy response evaluation to address this question. We found that in subjects with JAK2/BCR::ABL1 co-mutations there is a complex, branched clonal evolution. In contrast, in subjects with CALR/BCR::ABL1, co-mutations are in different sub-clones. There are too few data in subjects with MPL/BCR::ABL1 to critically analyze. However, indirect methods for assessing clonality limit our conclusions. Understanding clonal architecture of MPNs with co-mutations is needed to understand the underlying biology and give appropriate therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Janus Kinase 2Myeloproliferative DisordersReceptors, ThrombopoietinCalreticulinMutationFusion Proteins, bcr-ablProto-Oncogene Proteins c-ablProto-Oncogene Proteins c-bcrHumansClonal Evolution

Stichwörter der Autor:innen

Branching evolutionCMLClonal interactionsMPNsTyrosine kinase inhibitors

Substanzen

Janus Kinase 2Receptors, ThrombopoietinMPL protein, humanCalreticulinJAK2 protein, humanCALR protein, humanFusion Proteins, bcr-ablProto-Oncogene Proteins c-ablProto-Oncogene Proteins c-bcrABL1 protein, human

Autor:innen und Institutionen

  • Vali-E-Asr Reproductive Health Research Center, Family Health Research Institute, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: m.amin.noorafrooz@gmail.com.
  • Vali-E-Asr Reproductive Health Research Center, Family Health Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Centre for Haematology, Department of Immunology and Inflammation, Imperial College of Science, Technology and Medicine, London, UK.

Förderung

  • National Institute for Health and Care Research
  • NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research

Zitieren

APA

Noorafrooz, M., Ghods, S., Gale, R. P., & Noorafrooz, R. (2025). A Review of Clonal Relationships in Myeloproliferative Neoplasms With Co-Mutations of JAK2, CALR or MPL and BCR::ABL1. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2024.11.007

Vancouver

Noorafrooz M, Ghods S, Gale RP, Noorafrooz R. A Review of Clonal Relationships in Myeloproliferative Neoplasms With Co-Mutations of JAK2, CALR or MPL and BCR::ABL1. Clinical Lymphoma Myeloma and Leukemia. 2025. doi:10.1016/j.clml.2024.11.007

BibTeX
@article{Noorafrooz2025,
  author = {Noorafrooz, Mohammadamin and Ghods, Sanaz and Gale, Robert Peter and Noorafrooz, Ramin},
  title = {A Review of Clonal Relationships in Myeloproliferative Neoplasms With Co-Mutations of JAK2, CALR or MPL and BCR::ABL1},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2025},
  doi = {10.1016/j.clml.2024.11.007}
}
Kostenlos starten →